News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sapphire Therapeutics, Inc. Licenses Ghrelin Antagonist Program From Novo Nordisk A/S (NVO) for Development of Obesity Treatments


10/30/2007 9:10:24 AM

BRIDGEWATER, NJ--(Marketwire - October 30, 2007) - Sapphire Therapeutics, Inc., a private biopharmaceutical company that develops new medicines acting on the ghrelin receptor for metabolic and oncologic diseases, has licensed a discovery-stage ghrelin antagonist program from Novo Nordisk. Ghrelin receptor antagonists are a new therapeutic target for the continuing unmet need for improved obesity treatments.

Read at BioSpace.com


comments powered by Disqus
   
Obesity

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES